Why the study?
The study aimed to estimate the diagnostic accuracy of the VitalScan magnetocardiograph for suspected acute coronary syndrome.
Does the VitalScan magnetocardiograph accurately diagnose acute coronary syndrome in adults with suspected ACS?
Does the VitalScan magnetocardiograph accurately diagnose acute coronary syndrome in adults with suspected ACS?
Answers are grounded in this paper and cite their sources.
The VitalScan magnetocardiograph has poor diagnostic accuracy and is currently unable to accurately rule out acute coronary syndrome in clinical practice.
BACKGROUND: We aimed to estimate the diagnostic accuracy of the VitalScan magnetocardiograph (MCG) for suspected acute coronary syndrome (ACS). METHODS: We undertook a prospective cohort study evaluating the diagnostic accuracy of the MCG in adults with suspected ACS. The reference standard of ACS was determined by an independent adjudication committee based on 30-day investigations and events. The cohort was split into a training sample, to derive the MCG algorithm and an algorithm combining MCG with a modified Manchester Acute Coronary Syndrome (MACS) clinical probability score, and a validation sample, to estimate diagnostic accuracy. RESULTS: We recruited 756 participants and analysed data from 680 (293 training, 387 validation), of whom 96 (14%) had ACS. In the training sample, the respective area under the receiver operating characteristic (AUROC) curves were the following: MCG 0.66 (95% CI 0.58 to 0.74), MACS 0.64 (95% CI 0.54 to 0.73) and MCG+MACS 0.70 (95% CI 0.63 to 0.77). MCG specificity was 0.16 (95% CI 0.12 to 0.21) at the threshold achieving acceptable sensitivity for rule-out (>0.98). In the validation sample (n=387), the respective AUROCs were the following: MCG 0.56 (95% CI 0.48 to 0.64), MACS 0.69 (95% CI 0.61 to 0.77) and MCG+MACS 0.64 (95% CI 0.56 to 0.72). MCG sensitivity was 0.89 (95% CI 0.77 to 0.95) and specificity 0.15 (95% CI 0.12 to 0.20) at the rule-out threshold. MCG+MACS sensitivity was 0.85 (95% CI 0.73 to 0.92) and specificity 0.30 (95% CI 0.25 to 0.35). CONCLUSION: The VitalScan MCG is currently unable to accurately rule out ACS and is not yet ready for use in clinical practice. Further developmental research is required.
No takes yet. Share an insight, caveat, or question.
Goodacre et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: